PD-L1 Biomarkers
News and reporting on PD-L1 biomarkers.
European Commission Approves BeiGene's Tevimbra, Chemo in First-Line Gastric, Esophageal Cancers
The EC considered the treatment's activity in patients with advanced, PD-L1-positive esophageal and gastric cancers in the RATIONALE-305 and -306 trials.
Roche's Tiragolumab, Tecentriq Combo Misses Overall Survival Endpoint in PD-L1 Positive NSCLC Trial
The addition of tiragolumab to Tecentriq in patients with advanced PD-L1-high NSCLC failed to improve overall survival in a Phase III trial.
Arcus Confident in Anti-TIGIT, Immunotherapy, Chemo Regimen After Seeing Phase II Survival Data
Premium
The safety and overall survival seen in the ARC-10 trial lends further support to the firm's strategy of pairing domvanalimab and zimberelimab with chemo in STAR-121.
Cel-Sci, FDA Agree on Biomarker-Defined Confirmatory Study for Multikine
The trial, slated to begin next year, will enroll 200 patients with newly diagnosed, advanced head and neck cancer and low PD-L1 expression.
Akeso Begins Phase III Study of Anti-PD-1 Combo in Head and Neck Cancer
The firm is pitting a combination therapy targeting PD-1, VEGF, and CD47 against Keytruda in first-line advanced head and neck cancer.